Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $120.00

Nektar Therapeutics (NASDAQ:NKTR) had its price objective upped by HC Wainwright to $120.00 in a research note issued to investors on Tuesday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Nektar Therapeutics’ Q1 2026 earnings at ($3.00) EPS and Q3 2026 earnings at ($3.06) EPS.

Several other equities research analysts also recently issued reports on NKTR. William Blair restated a “market perform” rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. Jefferies Financial Group raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the company from $15.00 to $30.00 in a report on Friday, April 11th. Wall Street Zen downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 14th. Finally, Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 price objective for the company in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $76.43.

Nektar Therapeutics Price Performance

NKTR stock opened at $29.68 on Tuesday. The stock has a market capitalization of $368.33 million, a price-to-earnings ratio of -3.09 and a beta of 0.55. The company has a 50-day moving average of $11.19 and a two-hundred day moving average of $12.15. Nektar Therapeutics has a 52-week low of $6.48 and a 52-week high of $37.38.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing the consensus estimate of ($2.70) by ($0.60). The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter in the previous year, the company earned ($2.70) EPS. Equities analysts expect that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Nektar Therapeutics

Hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC boosted its position in shares of Nektar Therapeutics by 56.3% during the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 9,958 shares in the last quarter. Harvest Investment Services LLC bought a new position in Nektar Therapeutics during the fourth quarter worth about $27,000. US Asset Management LLC acquired a new stake in Nektar Therapeutics during the fourth quarter valued at approximately $31,000. Algert Global LLC bought a new stake in shares of Nektar Therapeutics in the 1st quarter valued at approximately $33,000. Finally, US Bancorp DE raised its holdings in shares of Nektar Therapeutics by 257.8% in the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 36,085 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.